159 related articles for article (PubMed ID: 25699116)
1. Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes.
Ohmura H; Mita T; Taneda Y; Sugawara M; Funayama H; Matsuoka J; Watada H; Daida H;
J Clin Med Res; 2015 Apr; 7(4):211-9. PubMed ID: 25699116
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients.
Kubota A; Maeda H; Kanamori A; Matoba K; Jin Y; Minagawa F; Obana M; Iemitsu K; Ito S; Amamiya H; Kaneshiro M; Takai M; Kaneshige H; Hoshino K; Ishikawa M; Minami N; Takuma T; Sasai N; Aoyagi S; Kawata T; Mokubo A; Takeda H; Honda S; Machimura H; Motomiya T; Waseda M; Naka Y; Tanaka Y; Terauchi Y; Matsuba I
J Diabetes Investig; 2012 Dec; 3(6):503-9. PubMed ID: 24843615
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer.
Kanamori A; Matsuba I
J Clin Med Res; 2013 Jun; 5(3):217-21. PubMed ID: 23671547
[TBL] [Abstract][Full Text] [Related]
4. Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a Hemoglobin A1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes.
Tajiri Y; Kawano S; Hirao S; Oshige T; Iwata S; Ono Y; Inada C; Akashi T; Hayashi H; Sato Y; Tojikubo M; Yamada K
Int Sch Res Notices; 2014; 2014():639489. PubMed ID: 27419209
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination.
Shimoda S; Iwashita S; Sekigami T; Furukawa N; Matsuo Y; Ichimori S; Goto R; Maeda T; Watanabe E; Kondo T; Matsumura T; Motoshima H; Nishida K; Araki E
J Diabetes Investig; 2014 May; 5(3):320-6. PubMed ID: 24843781
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.
Kondo Y; Harada N; Hamasaki A; Kaneko S; Yasuda K; Ogawa E; Harashima S; Yoneda H; Fujita Y; Kitano N; Nakamura Y; Matsuo F; Shinji M; Hinotsu S; Nakayama T; Inagaki N;
Diabetol Metab Syndr; 2016; 8():15. PubMed ID: 26925169
[TBL] [Abstract][Full Text] [Related]
8. Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus.
Katsuno T; Ikeda H; Namba M
Diabetes Ther; 2016 Jun; 7(2):309-20. PubMed ID: 27114254
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
[TBL] [Abstract][Full Text] [Related]
10. Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.
Yuasa S; Sato K; Takai M; Ishikawa M; Umezawa S; Kubota A; Maeda H; Kanamori A; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
J Clin Med Res; 2016 Jun; 8(6):461-71. PubMed ID: 27222674
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials.
Raji A; Long J; Lam RLH; O'Neill EA; Engel SS
Diabetes Ther; 2018 Aug; 9(4):1581-1589. PubMed ID: 29936573
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus and comparison of hypoglycemic action of concomitant medications: a subanalysis of the JAMP study.
Ujihara N; Sakura H; Hashimoto N; Sasamoto K; Ohashi H; Hasumi S; Kasahara T; Tomonaga O; Nunome H; Honda M; Iwamoto Y;
Diabetol Int; 2018 Feb; 9(1):56-65. PubMed ID: 30603350
[TBL] [Abstract][Full Text] [Related]
15. Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study.
Ishikawa M; Takai M; Maeda H; Kanamori A; Kubota A; Amemiya H; Iizuka T; Iemitsu K; Iwasaki T; Uehara G; Umezawa S; Obana M; Kaneshige H; Kaneshiro M; Kawata T; Sasai N; Saito T; Takuma T; Takeda H; Tanaka K; Tsurui N; Nakajima S; Hoshino K; Honda S; Machimura H; Matoba K; Minagawa F; Minami N; Miyairi Y; Mokubo A; Motomiya T; Waseda M; Miyakawa M; Naka Y; Terauchi Y; Tanaka Y; Matsuba I
J Clin Med Res; 2015 Aug; 7(8):607-12. PubMed ID: 26124906
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy.
Derosa G; D'Angelo A; Maffioli P
Pharmacol Res; 2015 Oct; 100():127-34. PubMed ID: 26211947
[TBL] [Abstract][Full Text] [Related]
17. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients.
Bando Y; Kanehara H; Aoki K; Hisada A; Toya D; Tanaka N
J Diabetes Investig; 2012 Mar; 3(2):170-4. PubMed ID: 24843561
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial.
Yokoh H; Kobayashi K; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K
J Diabetes Investig; 2015 Mar; 6(2):182-91. PubMed ID: 25802726
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
Langer J; Hunt B; Valentine WJ
J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.
Ogawa S; Ishiki M; Nako K; Okamura M; Senda M; Mori T; Ito S
Tohoku J Exp Med; 2011 Feb; 223(2):133-5. PubMed ID: 21304217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
